NCT04611308

Brief Summary

Globally, breast cancer is one of the most prevalent cancers in women and is the second leading cause of cancer death , representing 15% of worldwide deaths per year . In Egypt, it accounts for 32 % of cancer in women with a high mortality rate.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
102

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Nov 2020

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 27, 2020

Completed
5 days until next milestone

Study Start

First participant enrolled

November 1, 2020

Completed
1 day until next milestone

First Posted

Study publicly available on registry

November 2, 2020

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2021

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2022

Completed
Last Updated

November 2, 2020

Status Verified

October 1, 2020

Enrollment Period

11 months

First QC Date

October 27, 2020

Last Update Submit

October 27, 2020

Conditions

Breast Cancer

Outcome Measures

Primary Outcomes (1)

  • To investigate the CTRP6 levels in breast cancer.

    1 October 2021

Study Arms (2)

cases

Other: C1q tumor necrosis factor-related protein 6 levels

controls

Other: C1q tumor necrosis factor-related protein 6 levels

Interventions

C1q tumor necrosis factor-related protein 6 levelsOTHER

C1q tumor necrosis factor-related protein 6 is a tumor marker

casescontrols

Eligibility Criteria

Age18 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Approximately 102 cases.

You may qualify if:

  • Age: 18 years and older.
  • Newly diagnosed patients with histopathological confirmation of the diagnosis of breast cancer at any stage.

You may not qualify if:

  • Patients with a prior history of other cancers.
  • Patients with more than one cancer.
  • Patients treated with chemotherapy or radiotherapy before initial samples collection.
  • Pregnant women.
  • Patients with unqualified or insufficient data.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Breast Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsBreast DiseasesSkin DiseasesSkin and Connective Tissue Diseases

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Samia Farouk Hamed Ahmed

Study Record Dates

First Submitted

October 27, 2020

First Posted

November 2, 2020

Study Start

November 1, 2020

Primary Completion

October 1, 2021

Study Completion

October 1, 2022

Last Updated

November 2, 2020

Record last verified: 2020-10